Literature DB >> 11020469

Electrophoretic study of tartrate-resistant acid phosphatase isoforms in endstage renal disease and rheumatoid arthritis.

K Takahashi1, A J Janckila, S Z Sun, E D Lederer, P C Ray, L T Yam.   

Abstract

The objective of this study was to identify the isoform, type-5a or type-5b, responsible for increased tartrate-resistant acid phosphatase (TRAP) activity in endstage renal disease (ESRD) and TRAP protein in rheumatoid arthritis (RA). We studied 24 sera each from healthy, ESRD and RA subjects. Type-5 TRAP activity and protein were quantitated by immunoassays. Isoform expression was determined by computerized imaging of non-denaturing polyacrylamide gels (PAGE) stained for TRAP activity. Other biochemical markers included: intact parathyroid hormone (iPTH), total and bone-specific alkaline phosphatase (TAP, BAP), N-telopeptides of type-I collagen (NTx), and free pyridinoline (Pyd). Isoform 5a was normal in both ESRD and RA. Isoform 5b was elevated in ESRD only. Serum TRAP activity correlated with both isoforms 5a and 5b in RA, but only with 5b in ESRD. TRAP protein assays did not correlate with PAGE assays for 5a or 5b. TRAP activity, but not protein, correlated with BAP and NTx in RA sera. Both TRAP activity and protein correlated with iPTH, TAP and Pyd in ESRD sera. Increased TRAP activity in ESRD was due to increased osteoclastic isoform 5b and related to bone turnover. Increased TRAP protein in RA was suspected, but not proven, to be isoform 5a and not related to bone turnover. Heterogeneity of serum TRAP and preferential expression of isoforms has clinical significance in different diseases including ESRD and RA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020469     DOI: 10.1016/s0009-8981(00)00338-7

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Intensive weight gain therapy in patients with anorexia nervosa results in improved serum tartrate-resistant acid phosphatase (TRAP) 5a and 5b isoform protein levels.

Authors:  Christina Patlaka; Bojan Tubic; Pernilla Lång; Staffan Paulie; Diana Swolin-Eide; Per Magnusson; Göran Andersson
Journal:  Eat Weight Disord       Date:  2019-09-17       Impact factor: 4.652

2.  Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonates.

Authors:  Masakazu Nagashima; Hiroshi Takahashi; Kenichi Shimane; Yuichi Nagase; Koichi Wauke
Journal:  Arthritis Res Ther       Date:  2012-10-18       Impact factor: 5.156

3.  New Biochemical Serum Markers of Boneturnover in Renal Osteodystrophy.

Authors:  Magdalena Krintus; Agnieszka Pater; Gra Yna Sypniewska; Wies Aw Nowacki
Journal:  EJIFCC       Date:  2004-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.